KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 71 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $586,968 | +5.6% | 60,952 | -1.3% | 0.00% | – |
| Q2 2023 | $556,047 | +114548.9% | 61,783 | 0.0% | 0.00% | – |
| Q1 2023 | $485 | -50.6% | 61,783 | -10.4% | 0.00% | – |
| Q4 2022 | $982 | -99.9% | 68,946 | -13.6% | 0.00% | – |
| Q3 2022 | $1,158,000 | +48.7% | 79,778 | +0.7% | 0.00% | – |
| Q2 2022 | $779,000 | -19.0% | 79,243 | +24.0% | 0.00% | – |
| Q1 2022 | $962,000 | +20.9% | 63,905 | +1.3% | 0.00% | – |
| Q4 2021 | $796,000 | -66.1% | 63,100 | -48.3% | 0.00% | -100.0% |
| Q3 2021 | $2,351,000 | -19.8% | 122,122 | -0.2% | 0.00% | 0.0% |
| Q2 2021 | $2,932,000 | +126.1% | 122,359 | +47.3% | 0.00% | – |
| Q1 2021 | $1,297,000 | -18.5% | 83,090 | -0.9% | 0.00% | -100.0% |
| Q4 2020 | $1,592,000 | +14.1% | 83,838 | -24.3% | 0.00% | 0.0% |
| Q3 2020 | $1,395,000 | +4.3% | 110,791 | +0.2% | 0.00% | 0.0% |
| Q2 2020 | $1,338,000 | +209.0% | 110,535 | +95.0% | 0.00% | – |
| Q1 2020 | $433,000 | -38.4% | 56,672 | +43.5% | 0.00% | – |
| Q4 2019 | $703,000 | +88.0% | 39,479 | +22.6% | 0.00% | – |
| Q3 2019 | $374,000 | -72.7% | 32,200 | -48.0% | 0.00% | -100.0% |
| Q2 2019 | $1,372,000 | – | 61,906 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 422,310 | $10,849,000 | 5.86% |
| COMMODORE CAPITAL LP | 214,467 | $5,510,000 | 2.20% |
| Vivo Capital, LLC | 1,863,296 | $47,868,000 | 1.68% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 214,533 | $5,486,000 | 1.45% |
| Nicholas Investment Partners, LP | 594,130 | $15,263,000 | 1.06% |
| Altium Capital Management LP | 128,130 | $3,292,000 | 0.91% |
| Affinity Asset Advisors, LLC | 100,000 | $2,569,000 | 0.87% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,000 | $1,285,000 | 0.70% |
| APIS CAPITAL ADVISORS, LLC | 30,000 | $771,000 | 0.70% |
| Birchview Capital, LP | 40,000 | $1,028,000 | 0.61% |